|
【结 构 式】 
|
【药物名称】 【化学名称】2(S)-(3,5-Dimethylisoxazol-4-ylsulfonamido)-3-[3-(4-pyridinyl)-3-azaspiro[5.5]undec-9-ylcarboxamido]propionic acid 【CA登记号】 【 分 子 式 】C24H33N5O6S 【 分 子 量 】519.62451 |
【开发单位】Millennium (Originator), Lilly (Codevelopment) 【药理作用】Antiplatelet Therapy, Coagulation Disorders Therapy, HEMATOLOGIC DRUGS, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists |
合成路线1
The N-Boc protected azaspirocarboxylic acid (I) was simultaneously deprotected and esterified with ethanolic HCl to produce ester (II). Palladium-catalyzed coupling of azaspirocycle (II) with 4-bromopyridine (III) afforded the pyridyl-azaspirocarboxylic acid (IV). This was then condensed with the known amino ester (V) using EDC and HOBt to yield amide (VI). Finally, acid hydrolysis of the ethyl ester group of (VI) furnished the title compound.
| 【1】 Smyth, M.; Pandey, A.; Mehrota, M.; Scarborough, R.M. (COR Therapeutics, Inc.); Pyridyl-containing spirocyclic cpds. as inhibitors of fibrinogen-dependent platelet aggregation. WO 0130780 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 46838 | 3-(tert-butoxycarbonyl)-3-azaspiro[5.5]undecane-9-carboxylic acid | C16H27NO4 | 详情 | 详情 | |
| (II) | 46839 | ethyl 3-azaspiro[5.5]undecane-9-carboxylate | C13H23NO2 | 详情 | 详情 | |
| (III) | 23565 | 4-bromopyridine | 1120-87-2 | C5H4BrN | 详情 | 详情 |
| (IV) | 46840 | 3-(4-pyridinyl)-3-azaspiro[5.5]undecane-9-carboxylic acid | C16H22N2O2 | 详情 | 详情 | |
| (V) | 46841 | ethyl (2S)-3-amino-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]propanoate | C10H17N3O5S | 详情 | 详情 | |
| (VI) | 46842 | ethyl (2S)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-3-([[3-(4-pyridinyl)-3-azaspiro[5.5]undec-9-yl]carbonyl]amino)propanoate | C26H37N5O6S | 详情 | 详情 |